logo-loader

Insight Widest with the analysis. We look at the companies others don’t, giving access to the opportunities others won’t.

Deep dive: Industry & services

ANGLE’s Parsortix liquid biopsy proving to be more than just a...

The cancer detection system is “on track” for submission with the US FDA early in the fourth quarter,...

Proactive

11.48 Thu 23 Jan 2020

Open Orphan - Open Orphan PLC gets started on its rare disease mission
Deep dive: Health
Open Orphan recruits hVIVO for its rare disease mission
5 days, 20 hours ago
lab worker
Deep dive: Health
Scancell exploring new frontiers in cancer research
5 days, 20 hours ago
scientist at petrie dish
Deep dive: Health
Midatech Pharma sees big 18 months ahead as clinical trials build...
1 week, 2 days ago
Allergy Therapeutics PLC -
Deep dive: Health
Allergy Therapeutics:Profitable, growing and with strong product...
1 week, 3 days ago
Show all Insight news

Deep dive We explore the investor case for growth companies

Circassia Pharmaceuticals PLC - Health

Circassia Pharmaceuticals plots a path to profitability

2 weeks, 3 days ago
woman touching her skin Health

Integumen's digital revolution builds momentum

2 weeks, 3 days ago
antibodies Health

Avacta makes progress with development of affimer candidates

2 weeks, 4 days ago
Shield Therapeutics PLC - Health

Shield Therapeutics agrees deal in China for Feraccru

2 weeks, 4 days ago

Watch: director interviews Hear from the directors whose companies are making the new

Open Orphan Health

Full interview: Open Orphan confirms hVIVO deal is done

1 week, 4 days ago
Ergomed PLC - Ergomed net significant new acquisition Health

Full interview: Ergomed nets significant new acquisition

1 week, 6 days ago
Shield Therapeutics PLC - Shield Therapeutics ties up US$63mln deal for Feraccru in China Health

Full interview: Shield Therapeutics ties up US$63mln deal for...

2 weeks, 2 days ago
Open Orphan PLC - Open Orphan hails huge new deal leading to stronger revenues Health

Full interview: Open Orphan hails huge new deal leading to...

2 weeks, 2 days ago

Opinion We bridge the gap between knowledge and ignorance and give you the angle that hard facts alone won’t

Fevertree Drinks Plc - Retail & consumer

When did you get so big? Billion-pound companies that maybe you thought weren't

on 3/10/19

Feature We give you the knowledge and tools to understand and take on the market

Tesco PLC - One less Dave and one less Willie: Departure of Tesco and IAG bosses raises issue of diversity at the top Finance

One less Dave and one less Willie: Departure of Tesco and IAG bosses raises...

2 weeks, 3 days ago
Drugs Health

How much should a ‘blockbuster’ drug earn now?

on 25/12/19
AstraZeneca - AstraZeneca's near-£100bn valuation is a vindication for Pascal Soriot Health

AstraZeneca's near-£100bn valuation is a vindication for Pascal Soriot

on 27/11/19
Robinhood Finance

Robinhood's commission-free share trading a headache for investors or rivals?

on 20/11/19

Research Independent research from the expert Proactive analyst team

MaxCyte Inc - MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Strategic Minerals

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Health

Open Orphan 'continuing to...

Health

MaxCyte - Pole Position in...

MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow...

Health

Open Orphan: Leveraging...

Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic...

Health

Shield Therapeutics:...

Meet the real story
Proactive Investors One2One Investor Forum

BeProactive

Health

Immuno-oncology: All you wanted to know but were too afraid to ask

5 days, 16 hours ago
Finance

Explaining illegal market manipulation

on 12/8/19